Investors aren't applauding the potential merger, but one analyst points out what the advantages for both parties would be.
Tobacco giant Philip Morris International confirms it is in discussions with rival cigarette maker Altria Group in a potential all-stock deal that it calls 'a merger of equals.'
Farfetch denies it will be acquiring Barneys New York, which filed for bankruptcy earlier in August.
WageWorks receives an unsolicited and non-binding letter of interest from Mansa but says it 'unanimously rejects' the offer.
Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.
Recent speculation that the biotech giant would buy Alexion had boosted ALXN's shares. But Amgen just agreed to lay out $13.4 billion for Celgene's psoriasis drug.
With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.
Amgen's deal to buy Otezla from Celgene should not deter the drugmaker's stock from gaining ground over the long haul.
PDC Energy reaches an agreement to acquire SRC Energy in an all-stock deal valued at about $1.7 billion, including debt.
Amgen is finally making an expected splash out of its cash pile, but questions are abounding about the cost paid for Celgene's Otezla.